For an adult with type 2 diabetes and no contraindications, how do empagliflozin, luseogliflozin, and dapagliflozin compare in terms of efficacy, cardiovascular and renal outcomes, and recommended dosing?

Empagliflozin, Dapagliflozin, and Luseogliflozin Comparison

For adults with type 2 diabetes, empagliflozin and dapagliflozin demonstrate comparable cardiovascular and renal outcomes with similar safety profiles, while luseogliflozin lacks robust cardiovascular outcomes trial data and is not recommended in major international guidelines.

Evidence Quality and Drug Selection

The evidence base for SGLT-2 inhibitors is strongest for empagliflozin and dapagliflozin, both supported by large cardiovascular outcomes trials and included in major guidelines 1, 2, 3. Luseogliflozin is notably absent from American and European guidelines and lacks the cardiovascular outcomes data that define modern diabetes management.

Cardiovascular and Renal Outcomes: Head-to-Head Evidence

Recent real-world comparative effectiveness studies demonstrate no clinically meaningful differences between empagliflozin and dapagliflozin for major outcomes:

• A 2024 Scandinavian cohort study of 199,371 patients found equivalent risks for major cardiovascular events (HR 1.02,95% CI 0.97-1.08), heart failure (HR 1.05,95% CI 0.97-1.14), and serious renal events (HR 0.97,95% CI 0.87-1.07) 4

• A 2025 Danish target trial emulation with 50,283 patients showed comparable 6-year risks for acute kidney injury (18.2% vs 18.5%), chronic kidney disease progression (5.3% vs 5.7%), and albuminuria development 5

• A 2025 US claims database study of 657,814 patients confirmed similar MI/stroke risk (HR 0.98 for canagliflozin, HR 0.95 for dapagliflozin vs empagliflozin) 6

The key exception: Low-dose dapagliflozin 5 mg showed reduced benefit for heart failure hospitalization (HR 1.30,95% CI 1.12-1.50) compared to empagliflozin 6. This is clinically relevant because the effective dose matters.

Recommended Dosing

Empagliflozin: 10 mg once daily for cardiovascular/renal protection 1

Dapagliflozin: 10 mg once daily for cardiovascular/renal protection 1, 7

• The 5 mg dose is inadequate for heart failure benefits
• Can be initiated down to eGFR 25 mL/min/1.73 m² and continued to dialysis 2

Luseogliflozin: Not included in evidence-based guidelines; no established cardiovascular benefit dosing

Renal Function Thresholds

Empagliflozin:

• Initiate if eGFR ≥20 mL/min/1.73 m² 2, 3
• Continue once started even as eGFR declines
• Not recommended for glycemic control if eGFR <45 mL/min/1.73 m² 2

Dapagliflozin:

• Initiate if eGFR ≥25 mL/min/1.73 m² for kidney/CV benefits 2, 7
• Can continue to eGFR <20 mL/min/1.73 m² once established 2
• More flexible dosing at lower eGFR than empagliflozin

Safety Profile Differences

Both drugs share class effects but with subtle differences 6, 4:

Genital infections:

• Empagliflozin: 3.1%
• Dapagliflozin: 8.66% (higher risk, OR 0.92-0.94 vs empagliflozin) 8

Urinary tract infections:

• Empagliflozin: 2.34%
• Dapagliflozin: 7.08%
• Canagliflozin shows 13% higher severe UTI risk vs empagliflozin 6

Diabetic ketoacidosis:

• Dapagliflozin: 22% lower risk vs empagliflozin (OR 0.78,95% CI 0.68-0.90) 6

Shared class effects (all SGLT-2 inhibitors) 1, 2:

• Euglycemic ketoacidosis (withhold 3 days before surgery)
• Volume depletion (assess before initiating)
• Fournier gangrene (rare but serious)

Clinical Decision Algorithm

Step 1: Verify eGFR

• eGFR ≥25 mL/min/1.73 m²: Choose either empagliflozin 10 mg or dapagliflozin 10 mg
• eGFR 20-24 mL/min/1.73 m²: Empagliflozin 10 mg preferred (broader initiation range)
• eGFR <20 mL/min/1.73 m²: Initiation not recommended; continue if already established

Step 2: Consider infection history

• Recurrent genital mycotic infections: Empagliflozin preferred (lower risk)
• History of severe UTIs: Avoid canagliflozin; empagliflozin or dapagliflozin acceptable

Step 3: Dose selection

• Always use 10 mg for cardiovascular/renal benefits 1
• Never use dapagliflozin 5 mg for heart failure protection
• No dose titration needed for CV/renal outcomes

Step 4: Avoid luseogliflozin

• Lacks cardiovascular outcomes trial data
• Not included in evidence-based guidelines
• No established benefit for mortality or major adverse cardiovascular events

Common Pitfalls

1. Using dapagliflozin 5 mg for heart failure: This dose is ineffective for heart failure hospitalization reduction 6

2. Stopping at low eGFR: Continue SGLT-2 inhibitors as eGFR declines; kidney and CV benefits persist 2

3. Choosing luseogliflozin: This drug lacks the evidence base that defines modern SGLT-2 inhibitor therapy 1, 9

4. Forgetting surgical planning: Withhold at least 3 days before major surgery to prevent ketoacidosis 1

5. Ignoring volume status: Assess and correct volume depletion before initiating, especially in elderly patients or those on diuretics 1, 7

Guideline Consensus

The 2022 ADA/KDIGO consensus strongly recommends SGLT-2 inhibitors with proven kidney or cardiovascular benefit (empagliflozin, dapagliflozin, canagliflozin) for patients with type 2 diabetes, CKD, and eGFR ≥20 mL/min/1.73 m² 2. The 2024 BMJ guideline provides strong recommendations for SGLT-2 inhibitors at very high cardiovascular/kidney risk 10. Both empagliflozin and dapagliflozin meet these criteria; luseogliflozin does not appear in these guidelines.